new/era/mabs is a bootstrapped biotech company with a proprietary deep-tech antibody discovery platform for generating monoclonal and recombinant antibodies for research, diagnostics, or therapeutic applications. We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. Our core technology selma is a highly flexible mammalian cell display system based on novel transgenic cell lines. We offer the customized generation and manufacturing of antibody bundles (mouse, camelid, and human antibodies) as tools for various in vitro and in vivo applications. We are passionate experts in this field and eager to support your antibody projects.
Company Details
- Employees
- 4
- Founded
- -
- Address
- August-Bebel-Str. 89, Universität Potsdam,haus 7,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- neweramabs.com
- Keywords
- antibodies, immunotechnology, antibody discovery, selection of antibody producing cells, camelid phage display, recombinant antibodies, secondary antibodies.
- HQ
- Potsdam, Brandenburg
New/era/mabs Questions
New/Era/Mabs's website is neweramabs.com
New/Era/Mabs's LinkedIn profile is https://de.linkedin.com/company/neweramabs
New/Era/Mabs has
4 employees.
View email and phone details for 4
employees at New/Era/Mabs.
New/Era/Mabs's industry is
Biotechnology Research
New/Era/Mabs's top competitors are
Bit.bio Discovery,
Vital – A Barda Ban Hub,
Sensible Biotechnologies,
Spark At Stanford,
Apeiron Biologics Ag,
G.st Antivirals,
Cutanos Gmbh,
Silica Corpora,
Mucosatec,
Avocet Bio Gmbh.
New/Era/Mabs's categories are Biotechnology Research
New/Era/Mabs's founding year is 2014
